FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315702974> ?p ?o ?g. }

• W4315702974 abstract "Nanoparticles are the future of targeted and sustained drug delivery, yielding significant opportunities in addressing and treat challenging diseases such as cancer (Grenader et al., 2012; Luminari et al., 2010; Shoji et al., 2014). These nano vesicles can be developed into intelligent systems which can encapsulate medicinal and imaging agents, while still possessing stealth properties. Manipulating the size, surface properties, and material composition of these novel systems can help deliver drugs to specific tissues and provide controlled release therapy. Among them, lipid nanoparticles, particularly liposomes, have been identified as promising and adaptable drug vesicles. When compared to standard drug delivery systems, they have superior qualities such as site-targeting, prolonged or controlled release, drug protection from degradation and clearance, superior therapeutic efficacy, and lower toxic side effects. Liposomes are phospholipid vesicles that form approximately spherical bilayer shapes. These spherical vesicles can contain unilamellar or multilamellar internal concentric lipid bilayers trapping aqueous space. Due to this structure, liposomal vesicles allow for a wide variety of drugs with lipophilic and hydrophilic properties to be encapsulated simultaneously with hydrophobic/lipophilic molecules being inserted into the bilayer membrane and hydrophilic molecules being entrapped in the aqueous compartments. Beginning with Gabizon et al., 1982 and Tardi et al., 1985, liposome researchers have developed a wide range of liposomal drug carriers, by primarily employing small-scale laboratory techniques. The size of liposomes has a significant role in the effective delivery of anticancer drugs to the tumour site. Liposome size has been demonstrated to affect its time in blood circulation, tumour accumulation, tumour retention and the drug release. According to data so far, a liposome diameter of below 200 nm is the ideal size to achieve efficient drug delivery especially when targeting the brain and crossing the blood brain barrier (Gao et al., 2013; Kulkarni & Feng, 2013). This protocol aims to outline the steps involved in the synthesis of cationic and anionic liposomes with an approximate uniform size of 90 nm for targeted drug delivery in tumour cells. This method employed the use of thin-film dispersed hydration one of the most popular methods for preparing liposomes. References Gabizon, A. et al. (1982) “Liposomes as in Vivo Carriers of Adriamycin: Reduced Cardiac Uptake and Preserved Antitumor Activity in Mice,” American Association for Cancer Research, 42(11), pp. 4734–4739. PMID: 7127308 Gao, W. et al. (2013) “Liposome-like nanostructures for drug delivery,” Journal of Materials Chemistry B, 1(48), p. 6569. DOI:10.1039/C3TB21238F Grenader, T. et al. (2012) “Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin,” World Journal of Clinical Oncology, 3(10), p. 137. NIH [Online]. DOI: 10.5306/wjco.v3.i10.137 Kulkarni, S.A. and Feng, S.-S. (2013) “Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery,” Pharmaceutical Research, 30(10), pp. 2512–2522. PubMed [Online]. DOI: 10.1007/s11095-012-0958-3 Luminari, S. et al. (2010) “Nonpegylated liposomal doxorubicin (Myocet™) combination (R-comp) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): Results from the phase II EUR018 trial,” Annals of Oncology, 21(7), pp. 1492–1499. ScienceDirect [Online]. DOI: 10.1093/annonc/mdp544 Shoji, T. et al. (2014) “A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study),” Cancer Chemotherapy and Pharmacology, 73(5), pp. 895–901. SpringerLink [Online]. DOI: 10.1007/s00280-014-2418-8 Tardi, P., Boman, N. and Cullis, P. (1985) “Liposomal Doxorubicin,” Journal of Drug Targeting, 4(3), pp. 129–140. DOI: 10.3109/10611869609015970" @default.
• W4315702974 created "2023-01-12" @default.
• W4315702974 creator A5015488211 @default.
• W4315702974 date "2023-01-12" @default.
• W4315702974 modified "2023-10-18" @default.
• W4315702974 title "Liposome Synthesis Protocol : Synthesis of anionic and cationic unilamellar liposome nanoparticles using a thin film dispersed hydration and extrusion method. v1" @default.
• W4315702974 doi "https://doi.org/10.17504/protocols.io.dm6gpjyx1gzp/v1" @default.
• W4315702974 hasPublicationYear "2023" @default.
• W4315702974 type Work @default.
• W4315702974 citedByCount "0" @default.
• W4315702974 crossrefType "posted-content" @default.
• W4315702974 hasAuthorship W4315702974A5015488211 @default.
• W4315702974 hasBestOaLocation W43157029741 @default.
• W4315702974 hasConcept C12554922 @default.
• W4315702974 hasConcept C130316041 @default.
• W4315702974 hasConcept C13245373 @default.
• W4315702974 hasConcept C155672457 @default.
• W4315702974 hasConcept C171250308 @default.
• W4315702974 hasConcept C185154212 @default.
• W4315702974 hasConcept C185592680 @default.
• W4315702974 hasConcept C192157962 @default.
• W4315702974 hasConcept C192562407 @default.
• W4315702974 hasConcept C2778918659 @default.
• W4315702974 hasConcept C2779820397 @default.
• W4315702974 hasConcept C39944091 @default.
• W4315702974 hasConcept C41625074 @default.
• W4315702974 hasConcept C55493867 @default.
• W4315702974 hasConcept C86803240 @default.
• W4315702974 hasConceptScore W4315702974C12554922 @default.
• W4315702974 hasConceptScore W4315702974C130316041 @default.
• W4315702974 hasConceptScore W4315702974C13245373 @default.
• W4315702974 hasConceptScore W4315702974C155672457 @default.
• W4315702974 hasConceptScore W4315702974C171250308 @default.
• W4315702974 hasConceptScore W4315702974C185154212 @default.
• W4315702974 hasConceptScore W4315702974C185592680 @default.
• W4315702974 hasConceptScore W4315702974C192157962 @default.
• W4315702974 hasConceptScore W4315702974C192562407 @default.
• W4315702974 hasConceptScore W4315702974C2778918659 @default.
• W4315702974 hasConceptScore W4315702974C2779820397 @default.
• W4315702974 hasConceptScore W4315702974C39944091 @default.
• W4315702974 hasConceptScore W4315702974C41625074 @default.
• W4315702974 hasConceptScore W4315702974C55493867 @default.
• W4315702974 hasConceptScore W4315702974C86803240 @default.
• W4315702974 hasLocation W43157029741 @default.
• W4315702974 hasOpenAccess W4315702974 @default.
• W4315702974 hasPrimaryLocation W43157029741 @default.
• W4315702974 hasRelatedWork W1986027132 @default.
• W4315702974 hasRelatedWork W1993582666 @default.
• W4315702974 hasRelatedWork W1998599350 @default.
• W4315702974 hasRelatedWork W2054087967 @default.
• W4315702974 hasRelatedWork W2089532729 @default.
• W4315702974 hasRelatedWork W2122118872 @default.
• W4315702974 hasRelatedWork W2161536338 @default.
• W4315702974 hasRelatedWork W2971457390 @default.
• W4315702974 hasRelatedWork W4287126485 @default.
• W4315702974 hasRelatedWork W4315702974 @default.
• W4315702974 isParatext "false" @default.
• W4315702974 isRetracted "false" @default.
• W4315702974 workType "article" @default.